Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias?

Edward J. Mills, Dieter Ayers, Roger Chou, Kristian Thorlund

Research output: Contribution to journalArticle

7 Scopus citations


Determining the quality of a randomized clinical trial (RCT) is necessary for decision-makers to determine the believability and applicability of the trial findings. Issues that are likely to affect the utility of RCT evidence include issues of bias, random error and applicability. In this article we focus primarily on issues of bias and examine the evidence for whether reporting methodological items, including allocation concealment, sequence generation, and blinding of participants can be relied upon as evidence of bias. We present the findings of a systematic review of meta-epidemiological studies and a simulation study demonstrating that commonly examined sources of bias likely play little role in treatment exaggeration. We discuss other issues that may additionally influence trial outcomes including sample size, publication bias, and expertise of trialists. We conclude by discussing strategies to moderate the effect of known biases in assessing overall estimates of treatment effects.

Original languageEnglish (US)
Pages (from-to)2-7
Number of pages6
JournalContemporary Clinical Trials
Publication statusPublished - Apr 24 2015



  • Bias
  • Quality
  • Randomized clinical trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this